Stocks to Buy for Short Term: Axis Securities picks 2 largecaps and 3 midcaps for up to 11% gain in 15 days; check target price


Stock to Buy for 15 Days: Leading indices – BSE Sensex and Nifty 50 – recovered on Wednesday (May 21, 2025) after a lacklustre show in 3 consecutive trading sessions. Amid such market situations, brokerage Axis Securities has chosen 5 stocks for up to 15 days for a potential upside of 11 per cent. The stocks are from the defence, pharma and digital technology sectors. Check their target prices.

1. Data Patterns (defence sector)

Current Price: Rs 2,744.25 (BSE close on May 21)
Entry Price Range: Rs 2,700 – Rs 2,727
Stop Loss: Rs 2,670
Target: Rs 2,945

Reason for selection- The brokerage says that the midcap defence sector firm has a strong order book in the defence segment and the government’s PLI policy is driving the stock growth. The brokerage says a returns of up to 8 per cent is possible.

2. Shilpa Medicare (pharma sector)

Current Price: Rs 702.80 
Entry Price Range: Rs 714 – Rs 722
Stop Loss: Rs 707
Target: Rs 767
Reason for selection- The brokerage says that the midcap company’s hold in the API segment and new launches are expected to help it reach the target.

3. Affle India (digital ad-tech sector)

Current Price: Rs 1,701.80 
Entry Price Range: Rs 1,690 – Rs 1,707
Stop Loss: Rs 1,665
Target: Rs 1,833

Reason for selection- Axis Securities says that the largecap stock is seeing an upside of more than 8 per cent due to growth in the digital advertising market.

4. Krishna Institute of Medical Sciences (healthcare education)

Current Price: Rs 662.95 
Entry Price Range: Rs 651 – Rs 658
Stop Loss: Rs 642
Target: Rs 706
Reason for selection- Axis Securities says that due to the dual benefits of education and healthcare, the largecap stock is becoming the choice of investors.

Natco Pharma (pharma sector)

Current price: Rs 875.85 
Entry price range: Rs 871–Rs 879
Stop loss: Rs 848
Target: Rs 972
Reason for selection- The brokerage says that the midcap stock can give a return of up to 11 per cent due to the company’s presence in branded generics and the US market.



Source link

Author Profile
Managing Director at Bitlance Tech Hub | 09158211119 | [email protected] | Web

Anurag Dhole is a seasoned journalist and content writer with a passion for delivering timely, accurate, and engaging stories. With over 8 years of experience in digital media, she covers a wide range of topics—from breaking news and politics to business insights and cultural trends. Jane's writing style blends clarity with depth, aiming to inform and inspire readers in a fast-paced media landscape. When she’s not chasing stories, she’s likely reading investigative features or exploring local cafés for her next writing spot.

Leave a Reply

Your email address will not be published. Required fields are marked *